Abstract:Background: G protein-coupled receptors (GPCRs), the biggest family of signaling receptors, account for 34 % of all the drug targets approved by the Food and Drug Administration (FDA). It has been gradually recognized that GPCRs are of significance for tumorigenesis, but in-depth studies are still required to explore specific mechanisms. In this study, the role of GPCRs in hepatocellular carcinoma (HCC) was elucidated, and GPCR-related genes were employed for building a risk-score model for the prognosis and treatment efficacy prediction of HCC patients. Methods: Patients' data on HCC were sourced from the Liver Hepatocellular Carcinoma-Japan (LIRI-JP) and The Cancer Genome Atlas (TCGA) databases, while GPCR-related genes were obtained from the Molecular Signatures Database (MSigDB). Univariant and multivariant Cox regression analyses, as well as least absolute shrinkage and selection operator (LASSO) were performed with the aim of identifying differentially expressed GPCR-related genes and grouping patients. Differential expression and functional enrichment analyses were performed; protein-protein interaction (PPI) mechanisms were explored; hub genes and micro ribonucleic acid (miRNA)-target gene regulatory networks were constructed. The tumor immune dysfunction and exclusion (TIDE) algorithm was utilized to evaluate immune infiltration levels and genetic variations. Sensitivity to immunotherapy and common antitumor drugs was predicted via the database Genomics of Drug Sensitivity in Cancer (GDSC). Results: A GPCR-related risk score containing eight GPCR-related genes (atypical chemokine receptor 3 (ACKR3), C-C chemokine receptor type 3 (CCR3), CCR7, frizzled homolog 5 (FZD5), metabotropic glutamate receptor 8 (GRM8), hydroxycarboxylic acid receptor 1 (HCAR1), 5-hydroxytryptamine receptor 5A (HTR5A) and nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 6 (NLRP6)) was set up. In addition, patients were classified into groups with high and low risks. Patients in the high-risk group exhibited a worse prognosis but demonstrated a more favorable immunotherapy response rate compared with those in the low-risk group. Distinct sensitivity to chemotherapeutic drugs was observed. A clinical prediction model on the basis of GPCR-related risk scores was constructed. Areas under the curves (AUC) corresponding to one-, three- and five-year survival were 0.731, 0.765 and 0.731, respectively. Conclusions: In this study, an efficient HCC prognostic prediction model was constructed by only GPCR-related genes, which are all potential targets for HCC treatment.

GPR27 Regulates Hepatocellular Carcinoma Progression via MAPK/ERK Pathway

G Protein-Coupled Receptor 87 (Gpr87) Promotes The Growth And Metastasis Of Cd133(+) Cancer Stem-Like Cells In Hepatocellular Carcinoma

Human growth hormone and human prolactin function as autocrine/paracrine promoters of progression of hepatocellular carcinoma.

GPR56 facilitates hepatocellular carcinoma metastasis by promoting the TGF-β signaling pathway

GPRC5A: an Emerging Biomarker in Human Cancer

GPR27 expression correlates with prognosis and tumor progression in gliomas

A low level of GPR37 is associated with human hepatocellular carcinoma progression and poor patient survival

Down-regulation of GPR137 Expression Inhibits Proliferation of Colon Cancer Cells.

CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression

Knockdown of GPR137 by RNAi Inhibits Pancreatic Cancer Cell Growth and Induces Apoptosis

A Comprehensive Survival and Prognosis Analysis of GPR55 Expression in Hepatocellular Carcinoma.

GPR48 promotes multiple cancer cell proliferation via activation of Wnt signaling.

Protein Tyrosine Phosphatase Receptor S Acts As a Metastatic Suppressor in Hepatocellular Carcinoma by Control of Epithermal Growth Factor Receptor-Induced Epithelial-Mesenchymal Transition.

Overexpression of G Protein-Coupled Receptor GPR87 Promotes Pancreatic Cancer Aggressiveness and Activates NF-κB Signaling Pathway

Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion via Ras/MAPK Signaling Pathway

Exploration of prognostic and treatment markers in hepatocellular carcinoma via GPCR-related genes analysis

Role of microRNA-141-3p in the progression and metastasis of hepatocellular carcinoma cell

The Microtubule-Associated Protein PRC1 Promotes Early Recurrence of Hepatocellular Carcinoma in Association with the Wnt/β-catenin Signalling Pathway.

DEAD-box Helicase 27 Promotes Hepatocellular Carcinoma Progression Through ERK Signaling

Formylpeptide Receptor 1 Mediates the Tumorigenicity of Human Hepatocellular Carcinoma Cells

Inhibition of Glypican-3 Expression Via RNA Interference Influences the Growth and Invasive Ability of the MHCC97-H Human Hepatocellular Carcinoma Cell Line